1 day ago · Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion ...

1 day ago · Novo Nordisk is planning a new Phase 3 trial of its next-generation obesity drug CagriSema that will test different doses and longer duration of treatment, the company said Wednesday. The announcement comes six weeks after the Denmark-based company released data from another Phase 3 trial that underperformed executives’ expectations on weight ...

Dec 20, 2024 · Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).

2 days ago · Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in ...

1 day ago · Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its ...

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...

Bagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide.

2 days ago · In December, Novo said people who adhered to the CagriSema treatment plan achieved overall weight loss of 22.7% after 68 weeks, with 40.4% losing 25% or more. That was lower than the 25% across ...

1 day ago · Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December. ... Investors are growing anxious about Novo Nordisk’s silence since ...

Jul 17, 2023 · Clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes and weight management treatment. Developed by Novo Nordisk, CagriSema is a combination medication of cagrilintide and the GLP-1 receptor agonist semaglutide.